Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~- Postmenopausal women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- AMG 162 (Type: EXPERIMENTAL): 60 mg/mL denosumab given day 1, month 6, month 12 and month 18
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given day 1, month 6, month 12 and month 18

Based on this trial design, predict the completion outcome and termination type (if applicable).